Key Documents
Steven Foung
- Professor, Pathology
Contact Information
- Clinical Offices
Stanford Blood Center 3373 Hillview Ave MC 5556 Palo Alto, CA 94304 Telephone Work (650) 723-6481 Fax (650) 725-6610
- Academic Offices
Personal Information Email sfoung@stanford.eduAdministrative Contact Paochen Zhang Administrative Associate for Steven Foung Email paochenz@stanford.edu Tel Work 650-723-6481Not for medical emergencies or patient use
Clinical Focus
- Pathology
- Pathology and Laboratory Medicine
Administrative Appointments
- Associate Chair for Academic Affairs, Stanford University School of Medicine - Pathology , (2004– present )
Professional Education
- SUMC - Graduate Medical Education (1980) CA
- UCSF Medical Center (1977) CA
- San Francisco General Hospital (1976) CA
- UCSD Medical Center (1975) CA
Postdoctoral Advisees
Research Interests
Our research has focused on the early events of hepatitis C virus infection- virus attachment and entry to susceptible cells. The approach is through the generation of human monoclonal antibodies (HMAbs) to the virus envelope proteins with an emphasis on antibodies to conformational epitopes. A large panel of HMAbs has been produced with many broadly reactive to different HCV isolates common in the US and elsewhere. Functional studies showed some inhibiting the interaction of HCV envelope E2 protein with a putative receptor, CD81. Other studies found that these antibodies identify determinants on the surface of a recombinant virus particle (HCVpp) that resembles native infectious virions. The determinants are clustered in three distinct domains that appear to be similar to the antigenic structural and functional domains of other flavivirus envelope proteins. A finding supporting this model is that two of the three domains contain determinants that mediate virus neutralization as tested by the ability to block HCVpp infection in target cells. More recent findings with infectious HCV virions from cell culture confirmed early findings with HCVpp. Our findings support the view that virus entry is mediated by only specific determinants on the virus surface and appear to be restricted to distinct immunogenic domains. This is in contrast for other viruses, such as HIV, where the convention is that neutralization is the result of a critical number of any binding sites being occupied and preventing virus entry through steric hindrance. We intend to pursue studies on expanding this model of the virus envelope, which will be important in linking structure and function.
Publications
- J Gen Virol. 2009; (Pt 1): 48-58
- J Biol Chem. 2009; (36): 24622-33
- J Virol. 2008; (5): 2140-9
- Proc Natl Acad Sci U S A. 2008; (49): 19450-5
- J Virol. 2008; (13): 6711-20
- J Virol. 2008; (12): 6061-6
- J Virol. 2008; (12): 6067-72
- J Gen Virol. 2008; (Pt 3): 653-9
- Biochim Biophys Acta. 2008; (3): 530-42
- Curr Top Microbiol Immunol. 2008; 1-38
- J Virol. 2007; (15): 8101-11
- J Virol. 2007; (2): 1043-7
- J Biol Chem. 2006; (27): 18285-95
- J Virol. 2006; (6): 2654-64
- J Virol. 2006; (2): 866-74
- J Virol. 2005; (21): 13199-208
- Virology. 2005; (1): 438-53
- J Virol. 2004; (17): 9224-32
- J Virol. 2004; (13): 7257-63
- Bioorg Med Chem Lett. 2004; (17): 4529-32
- J Immunol. 2004; (1): 446-55
- J Virol. 2004; (6): 2994-3002
- J Biol Chem. 2003; (22): 20358-66
- J Virol. 2003; (2): 1604-9
- Virology. 2002; (1): 124-32
- AIDS Res Hum Retroviruses. 2002; (1): 57-70
- J Med Virol. 2001; (1): 23-9
- Blood. 2001; (13): 3745-9
- Blood. 2001; (4): 1023-6
- J Virol. 2000; (22): 10407-16
- J Virol. 1999; (2): 1205-12
- Transfus Med Rev. 1998; (2): 94-108
- J Infect Dis. 1998; (4): 855-62
- Br J Haematol. 1998; (3): 507-12
- Br J Haematol. 1998; (2): 318-24
- Blood. 1997; (5): 1977-81
- J Virol. 1997; (8): 5828-40
- J Virol. 1996; (11): 7349-59
- Science. 1996; (5248): 505-8
- Methods Mol Biol. 1995; 295-307
- J Clin Microbiol. 1995; (12): 3239-44
- Blood. 1995; (4): 1392-9
- Virology. 1994; (1): 321-8
- J Infect Dis. 1994; (3): 620-3
- Virus Genes. 1993; (4): 325-38
- Ann Neurol. 1993; (4): 411-4
- Virus Res. 1993; (1): 71-7
- J Acquir Immune Defic Syndr. 1993; (9): 1067-8
- J Clin Microbiol. 1993; (2): 260-4
- Jpn J Cancer Res. 1993; (2): 114-6
- Clin Immunol Immunopathol. 1993; (1): 40-9
- Blood. 1992; (10): 2789-96
- J Infect Dis. 1992; (5): 1160-3
- J Clin Microbiol. 1992; (4): 858-61
- J Infect Dis. 1991; (2): 400-3
- Hum Antibodies Hybridomas. 1991; (3): 155-9
- Neurology. 1991; (3): 448-50
- Vox Sang. 1991; (3): 171-6
- Gastroenterology. 1991; (6): 1724-7
- Transfusion. 1990 Jul-Aug; (6): 491-4
- J Immunol Methods. 1990; (1): 35-42
- Hum Immunol. 1990; (1): 65-9
- J Immunol Methods. 1990; (1): 43-50
- J Immunol Methods. 1989; (1): 117-22
- J Infect Dis. 1989; (3): 436-43
- West J Med. 1988; (1): 86-8
- Rev Fr Transfus Immunohematol. 1988; (2): 223-31
- J Immunol. 1987; (1): 104-8
- Vox Sang. 1987; (1): 44-7
- J Infect Dis. 1986; (3): 422-9
- Methods Enzymol. 1986; 168-74
- Vox Sang. 1986; (3): 160-3
- Hum Immunol. 1986; (3): 316-9
- Vox Sang. 1985; (3): 206-10
- J Infect Dis. 1985; (2): 280-5
- Vox Sang. 1985; (5): 305-8
- J Immunol Methods. 1984; (1): 83-90
- Proc Natl Acad Sci U S A. 1982; (23): 7484-8
- Hum Immunol. 1982; (1): 61-72
- Pediatr Ann. 1979; (6): 39-51
- J Nutr. 1978; (5): 759-65